GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Tax Rate %

Benitec Biopharma (Benitec Biopharma) Tax Rate % : 0.00% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Benitec Biopharma's Tax Expense for the three months ended in Mar. 2024 was $0.00 Mil. Benitec Biopharma's Pre-Tax Income for the three months ended in Mar. 2024 was $-4.28 Mil. Therefore, Benitec Biopharma's Tax Rate % for the quarter that ended in Mar. 2024 was 0.00%.


Benitec Biopharma Tax Rate % Historical Data

The historical data trend for Benitec Biopharma's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Tax Rate % Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Benitec Biopharma's Tax Rate % for the fiscal year that ended in Jun. 2023 is calculated as

Tax Rate %=Tax Expense (A: Jun. 2023 )/Pre-Tax Income (A: Jun. 2023 )
=0/-19.562
=0.00 %

Benitec Biopharma's Tax Rate % for the quarter that ended in Mar. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2024 )/Pre-Tax Income (Q: Mar. 2024 )
=0/-4.279
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benitec Biopharma Tax Rate % Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000